This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Williams, M. S. Articles by Marmur, J. D. Search for Related Content PubMed PubMed Citation Articles by Williams, M. S. Articles by Marmur, J. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID Medline Plus Health Information Angioplasty Blood Thinners

(Circulation. 1998;98:742-748.)
© 1998 American Heart Association, Inc.

Clinical Investigation and Reports

Activation of Platelets in Platelet-Rich Plasma by Rotablation Is Speed-Dependent and Can Be Inhibited by Abciximab (c7E3 Fab; ReoPro)

Marlene S. Williams, MD; Barry S. Coller, MD; Heikki J. Väänänen, MSc; Lesley E. Scudder, BSc; Samin K. Sharma, MD; ; Jonathan D. Marmur, MD

From the Divisions of Cardiology and Hematology, Department of Medicine, Mount Sinai School of Medicine, New York, NY.

Correspondence to Jonathan D. Marmur, MD, The Mount Sinai Medical Center, Division of Cardiology, Box 1030, One Gustave L. Levy Place, New York, NY 10029. E-mail jmarmur{at}smtplink.mssm.edu

Background—Rotational atherectomy with the Rotablator catheter has improved percutaneous treatment of certain coronary atherosclerotic lesions, but the "no-reflow" phenomenon remains a serious complication. Because platelet activation by rotablation may contribute to the no-reflow phenomenon, we developed an in vitro system to test the effect of rotablation on platelets in the absence or presence of platelet GP IIb/IIIa receptor blockade with abciximab.

Methods and Results—Platelet-rich plasma (PRP) was prepared from 28 healthy human volunteers. PRP was divided into 4 samples: (1) no treatment, (2) 6D1 (anti–GP Ib), (3) c7E3 Fab (anti–GP IIb/IIIa+_vß₃), and (4) c7E3 Fab+6D1. Samples were pumped through a flow chamber containing a 2.5-mm burr rotating at various speeds and then placed in an aggregometer. PRP samples tested in the absence of antibody underwent more rapid and extensive aggregation when rotablated at 150 000 and 180 000 rpm compared with 0 rpm (P<0.001 at both speeds). Preincubation of platelets with c7E3 Fab decreased the slope of aggregation at each rotablation speed, with 98%, 79%, and 71% reductions at 70 000, 150 000, and 180 000 rpm, respectively (P=0.09 for 70 000 and P<0.001 for both 150 000 and 180 000 rpm). Preincubation of platelets with 6D1 did not decrease the slope of aggregation at any rotablation speed (P>0.5, P=0.99, and P=0.091 for 70 000, 150 000, and 180 000 rpm). Platelet ATP release, a marker of granule release and cell damage, was markedly increased at 180 000 rpm (P=0.002 compared with 0 rpm in the control group). Electron microscopy revealed extensive rotablation-induced platelet damage at 150 000 and 180 000 rpm, and leakage of LDH confirmed platelet lysis at these speeds (P=0.002 and P<0.001 compared with 0 rpm).

Conclusions—High-speed rotablation induces platelet activation of PRP, leading to aggregation; pretreating PRP with abciximab decreases the aggregation. These data suggest that pretreatment of patients with abciximab may decrease rotablation-induced platelet aggregation during rotational atherectomy.

Key Words: platelets • platelet aggregation inhibitors • angioplasty

This article has been cited by other articles:

				D. Shimbo, W. Chaplin, S. Kuruvilla, L. T. Wasson, D. Abraham, and M. M. Burg Hostility and Platelet Reactivity in Individuals Without a History of Cardiovascular Disease Events Psychosom Med, September 1, 2009; 71(7): 741 - 747. [Abstract] [Full Text] [PDF]

				K. P. Bouki, G. Pavlakis, and E. Papasteriadis Management of Cardiogenic Shock Due to Acute Coronary Syndromes Angiology, March 1, 2005; 56(2): 123 - 130. [Abstract] [PDF]

				L. Mandinov, A. Mandinova, S. Kyurkchiev, D. Kyurkchiev, I. Kehayov, V. Kolev, R. Soldi, C. Bagala, E. D. de Muinck, V. Lindner, et al. Copper chelation represses the vascular response to injury PNAS, May 27, 2003; 100(11): 6700 - 6705. [Abstract] [Full Text] [PDF]

				J. vom Dahl, U. Dietz, P. K. Haager, S. Silber, L. Niccoli, H. J. Buettner, F. Schiele, M. Thomas, P. Commeau, D. R. Ramsdale, et al. Rotational Atherectomy Does Not Reduce Recurrent In-Stent Restenosis: Results of the Angioplasty Versus Rotational Atherectomy for Treatment of Diffuse In-Stent Restenosis Trial (ARTIST) Circulation, February 5, 2002; 105(5): 583 - 588. [Abstract] [Full Text] [PDF]

				S. H. Rezkalla and R. A. Kloner No-Reflow Phenomenon Circulation, February 5, 2002; 105(5): 656 - 662. [Full Text] [PDF]

				E Eeckhout and M.J Kern The coronary no-reflow phenomenon: a review of mechanisms and therapies Eur. Heart J., May 1, 2001; 22(9): 729 - 739. [PDF]

				T Dill, U Dietz, C.W Hamm, R Kuchler, H.-J Rupprecht, M Haude, J Cyran, C Ozbek, K.-H Kuck, J Berger, et al. A randomized comparison of balloon angioplasty versus rotational atherectomy in complex coronary lesions (COBRA study) Eur. Heart J., November 1, 2000; 21(21): 1759 - 1766. [Abstract] [PDF]

				K.-C. Koch, J. vom Dahl, E. Kleinhans, H. G. Klues, P. W. Radke, S. Ninnemann, G. Schulz, U. Buell, and P. Hanrath Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy J. Am. Coll. Cardiol., March 15, 1999; 33(4): 998 - 1004. [Abstract] [Full Text] [PDF]